Chemical Information
Antiviral agent ID	DrugRepV_3520
Antiviral agent name	Favipiravir
IUPAC Name	5-fluoro-2-oxo-1H-pyrazine-3-carboxamide
SMILES (canonical)	C1=C(N=C(C(=O)N1)C(=O)N)F
Molecular Formula	C5H4FN3O2
Molecular Weight (g/mol)	157.104
InChl	InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
Common Name	Favipiravir
Synonyms	T-705 | 6-fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide | 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide | avigan
Structural Information
Clinical Information
Category	Antiviral
Primary Indication (Clinical trial phases)	Investigational
Biological Information
Primary Indication (Disease Category)	Infectious Disease
Primary Indication (Disease)	Influenza virus
Secondary Indication	Influenza virus (IAV) H3N2v A/Ohio/88/2012
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	MDCK
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Viral titer)	0.001 MOI
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Time of drug delivery)	Post infection
Secondary Indication (Duration of drug delivery)	48 hours
Secondary Indication (Drug concentration)	2.85 ± 0.77 μM
Secondary Indication (Cell based assay)	Virus yield reduction assay
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	IC90 [ 90 % ]
Reference	Sleeman K, Mishin VP, Guo Z, Garten RJ, Balish A, Fry AM, Villanueva J, Stevens J, Gubareva LV..Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 20.Antimicrob Agents Chemother. 2014;58(4):2045-51. doi: 10.1128/AAC.02556-13. Epub 2014 Jan 21. PMID:24449767
Comment	Using cell culture assays, the investigational antiviral drugs nitazoxanide, favipiravir, and fludase were shown to inhibit the replication of A(H3N2)v viruses, including the virus with the S247P substitution in the neuraminidase